424 related articles for article (PubMed ID: 31895102)
1. Tumor uptake and associated greater efficacy of anti-Her2 immunoliposome does not rely on Her2 expression status: study of a docetaxel-trastuzumab immunoliposome on Her2+ breast cancer model (SKBR3).
Rodallec A; Sicard G; Giacometti S; Carre M; Maia T; Valette M; Bouquet F; Savina A; Lacarelle B; Ciccolini J; Fanciullino R
Anticancer Drugs; 2020 Jun; 31(5):463-472. PubMed ID: 31895102
[TBL] [Abstract][Full Text] [Related]
2. From 3D spheroids to tumor bearing mice: efficacy and distribution studies of trastuzumab-docetaxel immunoliposome in breast cancer.
Rodallec A; Sicard G; Giacometti S; Carré M; Pourroy B; Bouquet F; Savina A; Lacarelle B; Ciccolini J; Fanciullino R
Int J Nanomedicine; 2018; 13():6677-6688. PubMed ID: 30425482
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel-trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancer.
Rodallec A; Brunel JM; Giacometti S; Maccario H; Correard F; Mas E; Orneto C; Savina A; Bouquet F; Lacarelle B; Ciccolini J; Fanciullino R
Int J Nanomedicine; 2018; 13():3451-3465. PubMed ID: 29950829
[TBL] [Abstract][Full Text] [Related]
4. Anti-HER2 immunoliposomes for co-delivery of paclitaxel and rapamycin for breast cancer therapy.
Eloy JO; Petrilli R; Chesca DL; Saggioro FP; Lee RJ; Marchetti JM
Eur J Pharm Biopharm; 2017 Jun; 115():159-167. PubMed ID: 28257810
[TBL] [Abstract][Full Text] [Related]
5. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC
Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130
[TBL] [Abstract][Full Text] [Related]
6. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with
Al-Saden N; Lam K; Chan C; Reilly RM
Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
8. Development and Evaluation of Tri-Functional Immunoliposomes for the Treatment of HER2 Positive Breast Cancer.
Vaidya T; Straubinger RM; Ait-Oudhia S
Pharm Res; 2018 Mar; 35(5):95. PubMed ID: 29536232
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis.
Lewis Phillips GD; Nishimura MC; Lacap JA; Kharbanda S; Mai E; Tien J; Malesky K; Williams SP; Marik J; Phillips HS
Breast Cancer Res Treat; 2017 Aug; 164(3):581-591. PubMed ID: 28493046
[TBL] [Abstract][Full Text] [Related]
10. Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model.
Yamashita-Kashima Y; Shu S; Harada N; Fujimoto-Ouchi K
Oncol Rep; 2013 Sep; 30(3):1087-93. PubMed ID: 23783223
[TBL] [Abstract][Full Text] [Related]
11. Lapatinib and 17AAG reduce 89Zr-trastuzumab-F(ab')2 uptake in SKBR3 tumor xenografts.
Oude Munnink TH; de Vries EG; Vedelaar SR; Timmer-Bosscha H; Schröder CP; Brouwers AH; Lub-de Hooge MN
Mol Pharm; 2012 Nov; 9(11):2995-3002. PubMed ID: 23003202
[TBL] [Abstract][Full Text] [Related]
12. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.
Kirpotin DB; Drummond DC; Shao Y; Shalaby MR; Hong K; Nielsen UB; Marks JD; Benz CC; Park JW
Cancer Res; 2006 Jul; 66(13):6732-40. PubMed ID: 16818648
[TBL] [Abstract][Full Text] [Related]
13. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
Watanabe S; Yonesaka K; Tanizaki J; Nonagase Y; Takegawa N; Haratani K; Kawakami H; Hayashi H; Takeda M; Tsurutani J; Nakagawa K
Cancer Med; 2019 Mar; 8(3):1258-1268. PubMed ID: 30701699
[TBL] [Abstract][Full Text] [Related]
14. Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy.
Phillips GD; Fields CT; Li G; Dowbenko D; Schaefer G; Miller K; Andre F; Burris HA; Albain KS; Harbeck N; Dieras V; Crivellari D; Fang L; Guardino E; Olsen SR; Crocker LM; Sliwkowski MX
Clin Cancer Res; 2014 Jan; 20(2):456-68. PubMed ID: 24097864
[TBL] [Abstract][Full Text] [Related]
15. A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer.
Masuda N; Ohtani S; Takano T; Inoue K; Suzuki E; Nakamura R; Bando H; Ito Y; Ishida K; Yamanaka T; Kuroi K; Yasojima H; Kasai H; Takasuka T; Sakurai T; Kataoka TR; Morita S; Ohno S; Toi M
Breast Cancer Res Treat; 2020 Feb; 180(1):135-146. PubMed ID: 31953696
[TBL] [Abstract][Full Text] [Related]
16. Rapamycin-loaded Immunoliposomes Functionalized with Trastuzumab: A Strategy to Enhance Cytotoxicity to HER2-positive Breast Cancer Cells.
Eloy JO; Petrilli R; Brueggemeier RW; Marchetti JM; Lee RJ
Anticancer Agents Med Chem; 2017; 17(1):48-56. PubMed ID: 27225450
[TBL] [Abstract][Full Text] [Related]
17. Synergistic antitumor efficacy against the EGFRvIII+HER2+ breast cancers by combining trastuzumab with anti-EGFRvIII antibody CH12.
Xu W; Bi Y; Zhang J; Kong J; Jiang H; Tian M; Li K; Wang B; Chen C; Song F; Pan X; Shi B; Kong X; Gu J; Cai X; Li Z
Oncotarget; 2015 Nov; 6(36):38840-53. PubMed ID: 26474285
[TBL] [Abstract][Full Text] [Related]
18. Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment.
Askoxylakis V; Ferraro GB; Kodack DP; Badeaux M; Shankaraiah RC; Seano G; Kloepper J; Vardam T; Martin JD; Naxerova K; Bezwada D; Qi X; Selig MK; Brachtel E; Duda DG; Huang P; Fukumura D; Engelman JA; Jain RK
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26547932
[TBL] [Abstract][Full Text] [Related]
19. Feasibility of tailored, selective and effective anticancer chemotherapy by direct injection of docetaxel-loaded immunoliposomes into Her2/neu positive gastric tumor xenografts.
Yamamoto Y; Yoshida M; Sato M; Sato K; Kikuchi S; Sugishita H; Kuwabara J; Matsuno Y; Kojima Y; Morimoto M; Horiuchi A; Watanabe Y
Int J Oncol; 2011 Jan; 38(1):33-9. PubMed ID: 21109923
[TBL] [Abstract][Full Text] [Related]
20. Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody-cytotoxic drug conjugate.
Yamashita-Kashima Y; Yoshimura Y; Fujimura T; Shu S; Yanagisawa M; Yorozu K; Furugaki K; Higuchi R; Shoda J; Harada N
Cancer Chemother Pharmacol; 2019 Apr; 83(4):659-671. PubMed ID: 30659304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
